Compare SGHC & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGHC | CNTA |
|---|---|---|
| Founded | 2020 | 2020 |
| Country | Guernsey | United Kingdom |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.1B |
| IPO Year | 2021 | 2021 |
| Metric | SGHC | CNTA |
|---|---|---|
| Price | $13.52 | $39.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $17.33 | ★ $43.17 |
| AVG Volume (30 Days) | ★ 3.7M | 1.3M |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | N/A | ★ 29.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,000,000.00 |
| Revenue This Year | $16.09 | N/A |
| Revenue Next Year | $9.73 | N/A |
| P/E Ratio | $20.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.46 | $10.95 |
| 52 Week High | $14.38 | $40.26 |
| Indicator | SGHC | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 63.14 | 72.07 |
| Support Level | $10.18 | $39.36 |
| Resistance Level | $14.23 | $39.86 |
| Average True Range (ATR) | 0.58 | 0.12 |
| MACD | -0.02 | -0.24 |
| Stochastic Oscillator | 64.11 | 67.65 |
Super Group (SGHC) Ltd is a holding company that operates online sports betting and gaming businesses. The company's four operating segments-Betway, Spin, Jumpman and DGC. A majority of its revenue is generated from the Betway segment, which is a single-brand online sports betting and casino offering with licenses to operate throughout Europe, the Americas, and Africa. Spin is the company's multi-brand online casino offering, having a diverse portfolio of casino brands such as Jackpot City, Spin Casino, Dream Bingo, Mirror Bingo, etc., designed to be culturally relevant globally while aiming to offer a wide range of casino products. Geographically, the company generates maximum revenue from Africa and Middle East, followed by North America, Europe, Asia-Pacific, and South/Latin America.
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.